Press releases
* (R) = Regulatory press releases
Oct 14, 2022
(R) Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies
Sep 22, 2022
(R) Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy
Sep 15, 2022
(R) Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence
Aug 31, 2022
(R) New number of shares and votes in Cantargia
Aug 30, 2022
Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy
Aug 30, 2022
(R) Cantargia publishes half year report
Aug 17, 2022
Invitation to presentation of Cantargia’s report for the second quarter of 2022 on August 30 at 3.00 p.m. CET
Aug 12, 2022
